Welcome to our dedicated page for Bath & Body Works SEC filings (Ticker: BBWI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bath & Body Works, Inc. (NYSE: BBWI) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8‑K that furnish earnings releases and guidance updates. Recent 8‑K filings reference press releases detailing unaudited quarterly financial results, outlook for upcoming quarters and revisions to full-year guidance, which are incorporated by reference as exhibits.
Through these filings, investors can review information on net sales, operating income, net income and earnings per diluted share, as well as management’s commentary on business trends and strategic initiatives. Bath & Body Works uses 8‑K filings to distribute its quarterly results and to provide context on its Consumer First Formula transformation plan, which focuses on product innovation, brand building, marketplace expansion and operating efficiency.
On Stock Titan, BBWI filings are updated in near real time from the SEC’s EDGAR system and are paired with AI-powered summaries that explain the key points in clear language. These tools help readers quickly understand what each filing covers, such as changes in guidance, notable adjustments in reported versus adjusted results, or other material events disclosed under Regulation FD.
In addition to 8‑K reports, investors can use this page to locate Bath & Body Works’ periodic filings like annual reports on Form 10‑K and quarterly reports on Form 10‑Q, when available, for deeper detail on segment performance, risk factors and accounting policies. Insider transaction reports on Form 4, once filed, can also be accessed to analyze equity activity by directors and officers. The combination of original documents and AI-generated insights is intended to make BBWI’s regulatory history easier to navigate and interpret.
Bath & Body Works reported softer results for the fourth quarter and full-year 2025 while outlining a reset year for 2026. Fourth quarter 2025 net sales were $2.724 billion, down 2% from $2.788 billion, with earnings per diluted share of $1.99 and adjusted earnings of $2.05 versus $2.09 last year.
For full-year 2025, net sales were essentially flat at $7.291 billion, while earnings per diluted share fell to $3.11 from $3.61 and adjusted earnings slipped to $3.21 from $3.29. The company generated $1.102 billion of operating cash flow, repurchased 15.1 million shares for $400 million, and ended the year with $953 million of cash.
Looking to 2026, management forecasts net sales to decline 4.5% to 2.5% versus 2025 and full-year earnings per diluted share of $3.00–$3.25. Excluding expected gains and tax items, adjusted earnings are projected between $2.40 and $2.65, down from $3.21 in 2025, with forecast free cash flow of about $600 million.
Bath & Body Works, Inc. announced that it has issued a notice of redemption for any and all outstanding 6.694% Senior Notes due 2027. The redemption date will be April 10, 2026.
The redemption price will be the greater of 100% of the principal amount of the Notes being redeemed or the sum of the present values of the remaining scheduled principal and interest payments on those Notes, discounted to the redemption date on a semiannual basis at the applicable treasury rate plus 50 basis points, plus accrued interest to the redemption date.
Bath & Body Works, Inc. reported that Michael Wu stopped serving as Chief Legal Officer and Corporate Secretary effective February 24, 2026. The company has begun searching for a new Chief Legal Officer. Wu is expected to remain as a non-executive employee helping with the transition until about March 27, 2026, during which he will continue to receive his current compensation and benefits.
If he remains employed in good standing through that date and signs a release of claims, his departure will be treated as a termination without cause under his May 13, 2022 executive severance agreement, making him eligible for related payments and benefits. After separation, he will remain bound by ongoing restrictions, including perpetual confidentiality, a one-year non-solicitation covenant, and a nine-month non-competition covenant.
Bath & Body Works, Inc. received a Schedule 13G showing that AQR Capital Management, LLC and AQR Capital Management Holdings, LLC beneficially own 11,445,928 shares of common stock, representing 5.59% of the class as of 12/31/2025.
The AQR entities report shared power to vote and dispose of all these shares, with no sole voting or dispositive power. They certify the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control of Bath & Body Works.
Bath & Body Works, Inc. director reports open-market share purchase. A company director filed a Form 4 disclosing the purchase of 22,500 shares of Bath & Body Works common stock on 11/24/2025 at a weighted average price of $15.58 per share. After this transaction, the reporting person beneficially owns 40,379 common shares held directly. The filing notes that the purchase price reflects a weighted average, with individual trades executed between $15.575 and $15.58 per share, and that detailed trade-level pricing information will be made available upon request.
Bath & Body Works, Inc. (BBWI) director reported buying additional company stock. On 11/24/2025, the reporting person purchased 10,000 shares of common stock at a price of $15.58 per share. After this transaction, the director beneficially owned 285,522 shares, held directly. The filing is signed by an attorney-in-fact on behalf of the reporting person.
Bath & Body Works, Inc. (BBWI) director purchased additional company stock in the open market. On 11/21/2025, the reporting person bought 20,000 shares of common stock at a price of $15.035 per share, coded as a purchase transaction ("P").
After this transaction, the director beneficially owned 33,925 shares of Bath & Body Works common stock, held directly. The filing notes that the form was submitted for a single reporting person and was signed by an attorney-in-fact on 11/24/2025.
Bath & Body Works, Inc. (BBWI) director reported an open-market stock purchase. On 11/21/2025, the director bought 6,700 shares of common stock at a price of $14.855 per share. After this transaction, the director directly owns 48,175 shares of BBWI common stock. Additional indirect holdings include 12,925 shares held by the director's spouse and 9,900 shares each held in the Patricia M. Steinour Legacy Trust dated 10/14/2016 and the Stephen D. Steinour Dynasty Trust dated 6/1/2016. No derivative securities were reported.
Bath & Body Works, Inc. (BBWI) director reports open-market stock purchase. A director acquired 3,343 shares of common stock of Bath & Body Works, Inc. on 11/21/2025 in a reported purchase transaction at a price of $14.995 per share. Following this transaction, the director directly holds 21,554 shares of BBWI common stock. This filing is a routine Form 4 disclosure of insider share ownership and recent trading activity.
Bath & Body Works, Inc. (BBWI)3,469.552 shares of Bath & Body Works common stock at a weighted average price of
After this transaction, the director beneficially owns 17,481.552 shares held directly. The price represents a weighted average, with individual purchase prices ranging from